In Phase 1 trials, imaging showed what appeared to be tumor growth months after treatment. This signal, which normally prompts more surgery, was actually a massive immune response. For patients whose doctors waited, this "growth" resolved on its own, leading to positive long-term outcomes.
When Dr. Decker's discovery challenged established science, he faced intense skepticism. Instead of trying to convince others, he focused on deeply understanding the mechanism for himself. This internal conviction, built from rigorous hands-on work, was key to persevering for over 20 years.
Diakonos chose glioblastoma, the deadliest brain cancer, for its first trial. This counterintuitive strategy provided a faster data readout, powerful validation upon success, and a lower regulatory burden from the FDA—all critical advantages for an early-stage company.
Dr. Decker found that combining two known methods of "informing" dendritic cells yielded an exponential immune response, not an additive one. This unexpected quantitative result was not just a better formula, but a scientific puzzle that drove 25 years of research to understand the underlying mechanism.
Diakonos' personalized therapy piggybacks on the existing patient journey. The required tumor sample is collected during the standard-of-care surgery that glioblastoma patients already undergo. This integration minimizes patient burden and simplifies logistical hurdles for clinical adoption.
Unlike complex cell therapies requiring hospital stays, Diakonos' treatment is a quick outpatient injection. This simplified administration allows them to partner with community cancer centers, not just major research hospitals, dramatically increasing trial recruitment speed and potential market access.